Innovent's mazdutide superior to Trulicity in Phase III T2D trial [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The study results demonstrated that mazdutide was superior to Trulicity for glycaemic control, as well as showing multiple cardiometabolic benefits including weight loss, blood lipid, blood pressure, serum uric acid and liver enzymes. The Phase III DREAMS-2 trial (NCT05606913) investigating mazdutide in Chinese patients with T2D met the primary endpoint of reducing glycated haemoglobin (HbA1c) after 28 weeks. Key secondary endpoints also showed mazdutide's superior benefits in both glucose-lowering and weight loss. The safety profile was consistent with previous trials, with no new safety signals observed. DREAMS-2 is a non-inferiority, multi-centre, randomised Phase III trial which enrolled 731 patients to receive mazdutide 4mg, mazdutide 6mg or dulaglutide 1.5mg for 28 weeks. The company is also running a head-to-head study of mazdutide and Novo Nordisk's Ozempic (semaglutide), the DREAMS-3 study (NCT06184568). Innovent clinical development vice president Dr Lei Qian, sai
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review [Yahoo! Finance]Yahoo! Finance
- Top Research Reports for Novo Nordisk, QUALCOMM & Caterpillar [Yahoo! Finance]Yahoo! Finance
- Fire at Novo Nordisk office building under control [CNBC]CNBC
- Weight-Loss Upstart Viking Needs a Deal to Vie With Lilly and Novo [BNN Bloomberg (Canada)]BNN Bloomberg
- Weight-Loss Upstart Viking Needs a Deal to Vie With Lilly and Novo [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/17/24 - Form 6-K
- 5/17/24 - Form SD
- 5/15/24 - Form 6-K
- NVO's page on the SEC website